Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17802174 | 1.00 | KDM4E (0.35) | KDM4ESMYD3ANPEPERAP2JAK2 | |
| Hydrochloric Acid SCHEMBL31325968 | 0.98 | KDM4E (0.34) | KDM4ESMYD3ANPEPERAP2JAK2 | |
| Hydrochloric Acid SCHEMBL17802228 | 0.98 | KDM4E (0.34) | KDM4ESMYD3ANPEPERAP2JAK2 | |
| Hydrochloric Acid SCHEMBL17802226 | 0.98 | KDM4E (0.34) | KDM4ESMYD3ANPEPERAP2JAK2 | |
| SCHEMBL20659612 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL20529367 | 0.85 | — | — | |
| SCHEMBL18232482 | 0.79 | SMYD3 (0.41) | KDM4ESMYD3ANPEPERAP2 | |
| SCHEMBL25018476 | 0.77 | KDM4E (0.35) | KDM4EJAK2JAK1TYK2GRIN2B | |
| SCHEMBL28372087 | 0.77 | KDM4E (0.45) | KDM4ESMYD3ANPEPERAP2 | |
| SCHEMBL28372086 | 0.77 | KDM4E (0.45) | KDM4ESMYD3ANPEPERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4702026-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-26 | — | — | US | disclosed |
| US-20250019369-A1 | N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as CD38 inhibitors | Cerevance, Inc. (US) | 2025-01-16 | — | — | US | disclosed |
| US-20240368167-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-11-07 | — | — | US | disclosed |
| WO-2024226685-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| EP-4430034-A1 | N-(4-AMINOCYCLOHEXYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AS CD38 INHIBITORS | Cerevance, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| WO-2023084206-A1 | N-(4-AMINOCYCLOHEXYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AS CD38 INHIBITORS | CEREVANCE LTD (GB) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023084206-A1 | N-(4-AMINOCYCLOHEXYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AS CD38 INHIBITORS | CEREVANCE LTD (GB) | 2023-05-19 | — | — | WO | disclosed |
| EP-3227275-B1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-01-02 | — | — | EP | disclosed |
| EP-3390384-A1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | Astex Therapeutics Limited (GB) | 2018-10-24 | — | — | EP | disclosed |
| US-9840496-B2 | CD38 inhibitors and methods of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-9840496-B2 | CD38 inhibitors and methods of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| EP-3227275-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-10-11 | — | — | EP | disclosed |
| US-20170260164-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-09-14 | — | — | US | disclosed |
| US-20170260164-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-09-14 | — | — | US | disclosed |
| WO-2017103851-A1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017103851-A1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
| WO-2016087975-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | CD38, BCL9, BCL6B | KDM4E 2392/4885SMYD3 2766/4885ANPEP 3161/4885 |
| US-20240368167-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | KDM4E 1792/4885SMYD3 3464/4885ANPEP 294/4885 |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | KDM4E 1792/4885SMYD3 3464/4885ANPEP 294/4885 |
| US-20170260164-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | CD38, NQO1, NADK | KDM4E 2314/4885SMYD3 3429/4885ANPEP 1921/4885 |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | HPGDS, PTGS1, PTGIS | KDM4E 2711/4885SMYD3 2586/4885ANPEP 2556/4885 |
| US-20250019369-A1 | N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as CD38 inhibitors | CD38, CXCR4, P2RY1 | KDM4E 410/4885SMYD3 2760/4885ANPEP 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.